Vestipitant (INN) is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It is under development as a potential antiemetic and anxiolytic drug, and as a treatment for tinnitus and insomnia.
See also
NK1 receptor antagonist Aprepitant Casopitant Fosaprepitant L-733,060 Maropitant
References